https://doi.org/10.4081/aiua.2023.11897
Salvage cryotherapy for prostate cancer
Submitted: October 1, 2023
Accepted: October 23, 2023
Published: January 8, 2024
Accepted: October 23, 2023
Abstract Views: 321
PDF: 261
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Most men diagnosed with prostate cancer will be candidates for active treatment and 20 to 50% of patients treated with organ preserving strategies recur within the prostate. Optimal treatment of recurrence is controversial. Prostate cryosurgery has been increasingly used as primary, recurrence and focal treatment for prostate cancer. Methods: We analysed 55 patients submitted to cryotherapy as salvage treatment after recurrence. Results: Study population presented with a mean age of 70.9 ± 6.2 years, mean initial PSA of 7.6 ng/ml and average prostate volume by ultrasound of 43.2 ± 14.7 grams. Mean follow-up was of 18.0 months. Biochemical free survival at one year of follow-up was of 85%. Conclusions: Cryotherapy can be an effective and safe treatment for recurrence after primary curative treatment failure.
Finley DS and Belldegrun AS. Salvage cryotherapy for radiationrecurrent prostate cancer: outcomes and complications. Curr Urol Rep. 2011; 12:209-15.
DOI: https://doi.org/10.1007/s11934-011-0182-4
Autran-Gomez AM, Scarpa RM, Chin J. High-intensity focused ultrasound and cryotherapy as salvage treatment in local radiorecurrent prostate cancer. Urol Int. 2012; 89:373-9.
DOI: https://doi.org/10.1159/000339616
Duijzentkunst DA, et al. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol. 2016; 34:1521-1531.
DOI: https://doi.org/10.1007/s00345-016-1811-9
Golbari NM and Katz AE. Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review. Curr Urol Rep. 2017; 18:63.
DOI: https://doi.org/10.1007/s11934-017-0709-4
Lomas DJ, Woodrum DA, Mynderse LA. Salvage ablation for locally recurrent prostate cancer. Curr Opin Urol. 2021; 31:188-193.
DOI: https://doi.org/10.1097/MOU.0000000000000861
Bauman G, et al. Cryosurgery Versus Primary Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Primary Radiotherapy: A Propensity-Matched Survival Analysis. Cureus. 2020; 12:e7983.
DOI: https://doi.org/10.7759/cureus.7983
Artibani W, et al. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review. Urol Int. 2018; 100:251-262.
DOI: https://doi.org/10.1159/000481438
Gheorghe GS et al. Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer. Curr Oncol. 2021; 28:3331-3346.
DOI: https://doi.org/10.3390/curroncol28050289
Desai K, McManus JM, Sharifi N. Hormonal Therapy for Prostate Cancer. Endocr Rev. 2021; 42:354-373.
DOI: https://doi.org/10.1210/endrev/bnab002
Ferreira VV, et al. Cardiovascular complications of treatment for prostate cancer. Br J Hosp Med (Lond). 2022; 83:1-12.
DOI: https://doi.org/10.12968/hmed.2022.0334
Afferi L, Longoni M, Moschini M, et al. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy. Prostate Cancer Prostatic Dis. 2023.
DOI: https://doi.org/10.1038/s41391-023-00668-0
DE Nunzio C, et al. Androgen deprivation therapy and cardiovascular risk in prostate cancer. Minerva Urol Nephrol. 2022; 74:508-517.
DOI: https://doi.org/10.23736/S2724-6051.22.04847-9
Korczak J, Mardas M, Litwiniuk M, et al. Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia. Nutrients. 2023; 15:1631.
DOI: https://doi.org/10.3390/nu15071631
Grubmüller B, et al. Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. Curr Oncol. 2021; 28:2881-2892.
DOI: https://doi.org/10.3390/curroncol28040252
Ingrosso G, et al. Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Metaanalysis. Eur Urol Oncol. 2020; 3:183-197.
DOI: https://doi.org/10.1016/j.euo.2018.12.011
Siomos VJ, Barqawi A. The current status of cryotherapy and high-intensity focused ultrasound in the treatment of low-grade prostate cancer. Rev Recent Clin Trials. 2011; 6:171-6.
DOI: https://doi.org/10.2174/157488711795177840
Cho S, Kang SH. Current status of cryotherapy for prostate and kidney cancer. Korean J Urol. 2014; 55:780-8.
DOI: https://doi.org/10.4111/kju.2014.55.12.780
Erinjeri JP, Clark TW. Cryoablation: mechanism of action and devices. J Vasc Interv Radiol. 2010; 21(8 Suppl):S187-91.
DOI: https://doi.org/10.1016/j.jvir.2009.12.403
Korpan NN, Hochwarter G, Sellner F. Cryoscience and cryomedicine: new mechanisms of biological tissue injury following low temperature exposure. Experimental study. Klin Khir. 2009; (7-8):80-5.
Gage AA and Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998; 37:171-86.
DOI: https://doi.org/10.1006/cryo.1998.2115
Becher E, Lepor H. Oncological control following partial gland ablation for intermediate-risk prostate cancer. Urol Oncol. 2020; 38:671-677.
DOI: https://doi.org/10.1016/j.urolonc.2020.04.017
Shah TT, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol. 2019; 76:98-105.
DOI: https://doi.org/10.1016/j.eururo.2018.12.030
Bruce JY, et al. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012; 10:716-22.
Kongnyuy M, et al. Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients. Int J Hyperthermia. 2017; 33:810-813.
DOI: https://doi.org/10.1080/02656736.2017.1306121
Tan WP, et al., Oncological and Functional Outcomes for Men Undergoing Salvage Whole-gland Cryoablation for Radiation-resistant Prostate Cancer. Eur Urol Oncol. 2023; 6:289-294.
DOI: https://doi.org/10.1016/j.euo.2023.02.007
Abufaraj M, Siyam A, Ali MR, et al. Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review. Cancers (Basel). 2021; 13:244.
DOI: https://doi.org/10.3390/cancers13020244
Gontero P, et al. Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. J Urol. 2019; 202:725-731.
DOI: https://doi.org/10.1097/JU.0000000000000327
Marquis A, et al. Nightmares in Salvage Robot-assisted Radical Prostatectomy After Primary Radiation Therapy for Prostate Cancer: A Step by Step Tutorial. Eur Urol Open Sci. 2022; 43:62-67.
DOI: https://doi.org/10.1016/j.euros.2022.07.002
Pfister D, et al. Salvage radical prostatectomy after local radiotherapy in prostate cancer. Curr Opin Urol. 2021; 31: 194-198.
DOI: https://doi.org/10.1097/MOU.0000000000000873
How to Cite
e Brito, D. V., Pereira, J. A., Ferreira, A. M., Lourenço, M., Godinho, R., Pereira, B., Peralta, P., Conceiçao, P., Reis, M., & Rabaça, C. (2024). Salvage cryotherapy for prostate cancer . Archivio Italiano Di Urologia E Andrologia, 95(4). https://doi.org/10.4081/aiua.2023.11897
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.